Information
-
Trademark
-
87497304
-
International Classifications
-
Filing Date
June 20, 2017
6 years ago
-
Transaction Date
January 21, 2022
2 years ago
-
Status Date
April 05, 2021
3 years ago
-
Published for Opposition Date
January 02, 2018
6 years ago
-
Location Date
September 17, 2018
5 years ago
-
Status Code
606
-
Current Location
DIVISIONAL UNIT
Employee Name
HESIK, APRIL ANNE
-
Attorney Docket Number
S2986036
Attorney Name
Stephanie K. Wade
Law Office Assigned Location Code
N60
-
Owners
Case File Statements
- CC0000: Color is not claimed as a feature of the mark.
- DM0000: The mark consists of three semi-circles aligned next to each other. The first semi-circle has its vertical opening facing to the right. It is separated by a narrow white space from the second semi-circle, whose vertical opening faces to the left. The third semi-circle's vertical opening faces to the right. The tips of the circular apexes of the second and third semi circles are adjoined to each other.
- GS0011: Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use
- GS0051: Infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens
- GS0421: Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network
Case File Event Statements
-
4/5/2021 - 3 years ago
59 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Type: MAB6
-
4/5/2021 - 3 years ago
58 - ABANDONMENT - NO USE STATEMENT FILED
Type: ABN6
-
8/1/2020 - 3 years ago
57 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
7/31/2020 - 3 years ago
56 - EXTENSION 5 GRANTED
Type: EX5G
-
7/29/2020 - 3 years ago
55 - EXTENSION 5 FILED
Type: EXT5
-
7/29/2020 - 3 years ago
54 - TEAS EXTENSION RECEIVED
Type: EEXT
-
2/7/2020 - 4 years ago
53 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
2/5/2020 - 4 years ago
52 - EXTENSION 4 GRANTED
Type: EX4G
-
2/5/2020 - 4 years ago
51 - EXTENSION 4 FILED
Type: EXT4
-
2/5/2020 - 4 years ago
50 - TEAS EXTENSION RECEIVED
Type: EEXT
-
1/30/2020 - 4 years ago
49 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Type: ARAA
-
1/30/2020 - 4 years ago
48 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Type: REAP
-
1/21/2020 - 4 years ago
47 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Type: ARAA
-
1/21/2020 - 4 years ago
46 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Type: REAP
-
10/16/2019 - 4 years ago
45 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Type: ARAA
-
10/16/2019 - 4 years ago
44 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Type: REAP
-
8/22/2019 - 4 years ago
43 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
8/19/2019 - 4 years ago
42 - EXTENSION 3 GRANTED
Type: EX3G
-
8/19/2019 - 4 years ago
41 - EXTENSION 3 FILED
Type: EXT3
-
8/19/2019 - 4 years ago
40 - TEAS EXTENSION RECEIVED
Type: EEXT
-
2/19/2019 - 5 years ago
39 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
2/15/2019 - 5 years ago
38 - EXTENSION 2 GRANTED
Type: EX2G
-
2/15/2019 - 5 years ago
37 - EXTENSION 2 FILED
Type: EXT2
-
2/15/2019 - 5 years ago
36 - TEAS EXTENSION RECEIVED
Type: EEXT
-
9/18/2018 - 5 years ago
35 - CORRECTED NOA E-MAILED
Type: NOAC
-
9/18/2018 - 5 years ago
34 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
9/17/2018 - 5 years ago
33 - EXTENSION 1 GRANTED
Type: EX1G
-
8/20/2018 - 5 years ago
32 - EXTENSION 1 FILED
Type: EXT1
-
9/17/2018 - 5 years ago
31 - DIVISIONAL PROCESSING COMPLETE
Type: DPCC
-
8/21/2018 - 5 years ago
30 - DIVISIONAL REQUEST RECEIVED
Type: DRRR
-
9/17/2018 - 5 years ago
29 - CASE ASSIGNED TO INTENT TO USE PARALEGAL
Type: AITU
-
8/21/2018 - 5 years ago
28 - TEAS REQUEST TO DIVIDE RECEIVED
Type: ERTD
-
8/20/2018 - 5 years ago
27 - TEAS EXTENSION RECEIVED
Type: EEXT
-
2/27/2018 - 6 years ago
26 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Type: NOAM
-
2/20/2018 - 6 years ago
25 - CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Type: CHPB
-
2/16/2018 - 6 years ago
24 - ASSIGNED TO PETITION STAFF
Type: APET
-
2/6/2018 - 6 years ago
23 - TEAS POST PUBLICATION AMENDMENT RECEIVED
Type: EPPA
-
1/2/2018 - 6 years ago
22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
1/2/2018 - 6 years ago
21 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
12/13/2017 - 6 years ago
20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
11/26/2017 - 6 years ago
19 - ASSIGNED TO LIE
Type: ALIE
-
11/14/2017 - 6 years ago
18 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
11/14/2017 - 6 years ago
17 - EXAMINER'S AMENDMENT ENTERED
Type: XAEC
-
11/14/2017 - 6 years ago
16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Type: GNEN
-
11/14/2017 - 6 years ago
15 - EXAMINERS AMENDMENT E-MAILED
Type: GNEA
-
11/14/2017 - 6 years ago
14 - EXAMINERS AMENDMENT -WRITTEN
Type: CNEA
-
11/10/2017 - 6 years ago
13 - PREVIOUS ALLOWANCE COUNT WITHDRAWN
Type: ZZZX
-
11/10/2017 - 6 years ago
12 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
11/9/2017 - 6 years ago
11 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
11/8/2017 - 6 years ago
10 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
11/8/2017 - 6 years ago
9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
7/24/2017 - 6 years ago
8 - NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Type: GEAN
-
7/24/2017 - 6 years ago
7 - EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Type: GEAP
-
7/24/2017 - 6 years ago
6 - COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Type: EPEN
-
7/24/2017 - 6 years ago
5 - EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Type: CPEA
-
7/17/2017 - 6 years ago
4 - ASSIGNED TO EXAMINER
Type: DOCK
-
6/28/2017 - 6 years ago
3 - NOTICE OF DESIGN SEARCH CODE E-MAILED
Type: MDSC
-
6/27/2017 - 6 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Type: NWOS
-
6/23/2017 - 6 years ago
1 - NEW APPLICATION ENTERED IN TRAM
Type: NWAP